Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance

English version České info

Background:
The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is centred in North London, with over 400 cases diagnosed since 1995. In the current study, we evaluated the genetic variation in a subset of clinical samples from the outbreak with the hypothesis that these isolates have unique biological characteristics that have served to prolong the outbreak.

Methods:
Fitness assays, mutation rate estimation, and whole-genome sequencing were performed to test for selective advantage and compensatory mutations.

Results:
This detailed analysis of the genetic variation of these INH-R samples suggests that this outbreak consists of successful, closely related, circulating strains with heterogeneous resistance profiles and little or no associated fitness cost or impact on their mutation rate.

Conclusions:
Specific deletions and SNPs could be a peculiar feature of these INH-R M. tuberculosis isolates, and could potentially explain their persistence over the years.

Keywords:
Mycobacterium tuberculosis Whole-genome sequencing Fitness Mutation rate

Autoři: Giovanni Satta ^1,2*; Adam A. Witney ³; Robert J. Shorten ^1,4; Magdalena Karlikowska ¹; Marc Lipman ^5,6; Timothy D. Mchugh ¹
Působiště autorů: Department of Infection, Centre for Clinical Microbiology, University College London, London, UK. ¹; Imperial College Healthcare NHS Trust, London, UK. ²; Institute of Infection and Immunity, St George’s, University of London, London, UK. ³; Public Health Laboratory Manchester, Manchester Royal Infirmary, Manchester, UK. ⁴; Royal Free London NHS Foundation Trust, London, UK. 6UCL Respiratory, Division of Medicine, University College London, London, UK. ⁵
Vyšlo v časopise: BMC Medicine 2016, 14:117
Kategorie: Research article
prolekare.web.journal.doi_sk: https://doi.org/10.1186/s12916-016-0659-6

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The electronic version of this article is the complete one and can be found online at: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0659-6

Souhrn

Methods:
Fitness assays, mutation rate estimation, and whole-genome sequencing were performed to test for selective advantage and compensatory mutations.

Conclusions:
Specific deletions and SNPs could be a peculiar feature of these INH-R M. tuberculosis isolates, and could potentially explain their persistence over the years.

Keywords:
Mycobacterium tuberculosis Whole-genome sequencing Fitness Mutation rate

Zdroje

1. World Health Organization. Global tuberculosis report 2015, last accessed on 3 May 2016: www.who.int/tb.

2. Huyen MN, Cobelens FG, Buu TN, Lan NT, Dung NH, Kremer K, Tiemersma EW, van Soolingen D. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother. 2013;57(8):3620–7.

3. Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS. 2011;6(7):e22927.

4. Ruddy MC, Davies AP, Yates MD, et al. Outbreak of isoniazid resistant tuberculosis in north London. Thorax. 2004;59:279–85.

5. Maguire H, Ruddy M, Bothamley G, et al. Multidrug resistance emerging in North London outbreak. Thorax. 2006;61(6):547–8.

6. Maguire H, Brailsford S, Carless J, et al. Large outbreak of isoniazidmonoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. Euro Surveill. 2011;16(13).

7. Shorten RJ, McGregor AC, Platt S, Jenkins C, et al. When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak. J Antimicrob Chemother. 2013;68(3):543–9.

8. Shorten RJ. The Molecular Epidemiology of Mycobacterium tuberculosis in North London. PhD Thesis. University College London, London. http://discovery.ucl.ac.uk/1310448/1/1310448.pdf. Accessed 8 Aug 2016.

9. Maguire H, Dale JW, McHugh TD, et al. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax. 2002;57(7):617–22.

10. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. CMI. 2009;15(1):66–8.

11. Gillespie SH, Billington OJ, Breathnach A, et al. Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts. Microb Drug Resist. 2002;8:273–9.

12. O’Sullivan DM, McHugh TD, Gillespie SH. The effect of oxidative stress on the mutation rate of Mycobacterium tuberculosis with impaired catalase/peroxidase function. J Antimicrob Chemother. 2008;62:709–12.

13. Comas I, Borrell S, Roetzer, et al. Whole-genome sequencing of rifampicinresistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2011;44(1):106–10.

14. Musser JM. Single nucleotide polymorphisms in Mycobacterium tuberculosis structural genes. Emerg Infect Dis. 2001;7:486–7.

15. Tsolaki AG, et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A. 2004;101:4865–70.

16. Heym B, Alzari PM, Honore N. Missense mutations in the catalaseperoxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995;15:235–45.

17. O’Sullivan DM, McHugh TD, Gillespie SH. Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J Med Microbiol. 2010;59:1533–5.

18. Pope CF, O’Sullivan DM, McHugh TD, et al. A practical guide to measuring mutation rates in antibiotic resistance. Antimicrob Agents Chemother. 2008; 52:1209–14.

19. Walker TM, Ip CL, Harrell RH, et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2013;13(2):137–46.

20. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 26th May 2013. Available to download from Cornell University Library. https://arxiv.org/abs/1303.3997. Accessed 8th Aug 2016.

21. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–9.

22. Witney AA, Gould KA, Arnold A, et al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol. 2015;53(5):1473–83.

23. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and postanalysis of large phylogenies. Bioinformatics. 2014;30(9):1312–3.

24. Yang Z. PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol. 2007;24(8):1586–91.

25. Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639–45.

26. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, Cabibbe AM, Niemann S, Fellenberg K. PhyResSE: web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from wholegenome sequencing data. J Clin Microbiol. 2015;53(6):1908–14.

27. Forrellad MA, Klepp LI, Gioffré A, et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence. 2013;4(1):3–66.

28. Hu Y, Hoffner S, Jiang W, et al. Extensive transmission of isoniazid resistant M. tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study. BMC Infect Dis. 2010;10:43.

29. Gagneux S, Burgos MV, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid resistance in Mycobacterium tuberculosis. PloS Pathol. 2006;2:e61.

30. Ranganathan S, Bai G, Lyubetskaya A, et al. Characterization of a cAMP responsive transcription factor, Cmr (Rv1675c), in TB complex mycobacteria reveals overlap with the DosR (DevR) dormancy regulon. Nucleic Acids Res. 2016;44(1):134–51.

31. Gazdik MA, Bai G, Wu Y, McDonough KA. Rv1675c (cmr) regulates intramacrophage and cyclic AMP-induced gene expression in Mycobacterium tuberculosis-complex mycobacteria. Mol Microbiol. 2009;71(2):434–48.

32. Raynaud C, Guilhot C, Rauzier J, et al. Phospholipases C are involved in the virulence of Mycobacterium tuberculosis. Mol Microbiol. 2002;45:203–17.

33. Titball RW. Bacterial phospholipases C. Microbiol Rev. 1993;57:347–66.

34. Viana-Niero C, De Haas PE, Van Soolingen D, Leão SC. Analysis of genetic polymorphisms affecting the four phospholipase C (plc) genes in Mycobacterium tuberculosis complex clinical isolates. Microbiology. 2004;150:967–78.

35. Yang Z, Yang D, Kong Y, et al. Clinical relevance of Mycobacterium tuberculosis plcD gene mutations. Am J Respir Crit Care Med. 2005;171(12):1436–42.

36. Musser JM, Amin A, Ramaswamy S. Negligible genetic diversity of Mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure. Genetics. 2000;155:7–16.

37. Fraser CM, Eisen J, Fleishmann, et al. Comparative genomics and understanding of microbial biology. Emerg Infect Dis. 2000;6:505–12.

38. Kapur V, Whittam TS, Musser JM. Is Mycobacterium tuberculosis 15,000 years old? J Infect Dis. 1994;170:1348–9.

39. Sreevatsan S, Pan X, Stockbauer KE, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination. Proc Natl Acad Sci U S A. 1997;94:9869–74.

40. Ramaswanny SW, Amin AG, Goksel S, et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000;44:326–36.

Článok vyšiel v časopise